POTENTIAL TARGETS FROM HUMAN (RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES)1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Seq. Identity (%)	View	Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	1cly	IGG FAB (HUMAN IGG1, KAPPA) (Homo sapiens)	5 / 12	VAL H 171 VAL H 191 SER H 189 ASN H 209 ASN H 162	None	1.44A	20.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	2fl5	IMMUNOGLOBULIN IGG1 HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 171 VAL H 191 SER H 189 ASN H 209 ASN H 162	None	1.39A	22.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	3g04	HUMAN THYROID STIMULATING AUTOANTIBODY M22 HEAVY CHAIN (Homo sapiens)	5 / 12	VAL B 163 VAL B 182 SER B 180 ASN B 197 ASN B 155	None	1.44A	21.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	3mlx	HUMAN MONOCLONAL ANTI-HIV-1 GP120 V3 ANTIBODY 3074 FAB HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 163 VAL H 182 SER H 180 ASN H 197 ASN H 155	None	1.43A	20.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	6 / 12	ASP A 110 VAL A 111 SER A 192 PHE A 345 PHE A 346 TYR A 373	ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 (-3.3A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	0.87A	29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	6 / 12	ASP A 110 VAL A 111 SER A 192 PHE A 345 PHE A 346 TYR A 373	ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 (-3.3A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	1.02A	29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	6 / 12	ASP A 110 VAL A 111 SER A 196 PHE A 345 PHE A 346 TYR A 373	ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 ( 4.6A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	0.65A	29.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	8 / 12	TRP A 109 ASP A 113 VAL A 114 SER A 207 PHE A 289 PHE A 290 ASN A 312 TYR A 316	None ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) ERC  A1201 (-2.7A) ERC  A1201 (-4.5A) ERC  A1201 (-4.8A) ERC  A1201 (-3.0A) None	1.32A	42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	12 / 12	TRP A 109 ASP A 113 VAL A 114 VAL A 117 PHE A 193 SER A 203 SER A 207 PHE A 289 PHE A 290 ASN A 293 ASN A 312 TYR A 316	None ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) None ERC  A1201 (-4.4A) ERC  A1201 (-2.8A) ERC  A1201 (-2.7A) ERC  A1201 (-4.5A) ERC  A1201 (-4.8A) ERC  A1201 (-3.5A) ERC  A1201 (-3.0A) None	0.38A	42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	6 / 12	VAL A 117 SER A 204 SER A 207 ASN A 293 ASN A 312 TYR A 316	None ERC  A1201 ( 4.1A) ERC  A1201 (-2.7A) ERC  A1201 (-3.5A) ERC  A1201 (-3.0A) None	1.42A	42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	5 / 12	VAL A 117 SER A 207 PHE A 289 ASN A 312 TYR A 316	None ERC  A1201 (-2.7A) ERC  A1201 (-4.5A) ERC  A1201 (-3.0A) None	1.30A	42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	5 / 12	TRP A 109 ASP A 113 VAL A 114 SER A 203 PHE A 261	None CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.3A) CAU  A 500 (-4.2A)	1.39A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	6 / 12	TRP A 109 ASP A 113 VAL A 114 SER A 207 PHE A 262 TYR A 288	None CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.1A) CAU  A 500 (-4.6A) CAU  A 500 (-4.6A)	1.48A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	10 / 12	TRP A 109 ASP A 113 VAL A 114 VAL A 117 PHE A 193 PHE A 261 PHE A 262 ASN A 265 ASN A 284 TYR A 288	None CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.2A) CAU  A 500 (-4.5A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A) CAU  A 500 (-3.4A) CAU  A 500 (-3.3A) CAU  A 500 (-4.6A)	0.57A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	9 / 12	TRP A 109 ASP A 113 VAL A 114 VAL A 117 PHE A 193 SER A 203 PHE A 261 PHE A 262 TYR A 288	None CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.2A) CAU  A 500 (-4.5A) CAU  A 500 (-3.3A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A) CAU  A 500 (-4.6A)	0.65A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	5 / 12	TRP A 109 VAL A 114 PHE A 193 SER A 203 SER A 207	None CAU  A 500 (-3.5A) CAU  A 500 (-4.5A) CAU  A 500 (-3.3A) CAU  A 500 (-4.1A)	0.97A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	5 / 12	TRP A 109 VAL A 114 PHE A 193 SER A 207 ASN A 265	None CAU  A 500 (-3.5A) CAU  A 500 (-4.5A) CAU  A 500 (-4.1A) CAU  A 500 (-3.4A)	0.90A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	5 / 12	VAL A 117 PHE A 261 ASN A 265 ASN A 284 TYR A 288	CAU  A 500 (-4.2A) CAU  A 500 (-4.2A) CAU  A 500 (-3.4A) CAU  A 500 (-3.3A) CAU  A 500 (-4.6A)	1.24A	58.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	4i77	LEBRIKIZUMAB HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 163 VAL H 182 SER H 180 ASN H 197 ASN H 155	None	1.45A	21.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	4ib4	CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	7 / 12	TRP A 131 ASP A 135 VAL A 136 PHE A 340 PHE A 341 ASN A 344 TYR A 370	None ERM  A2001 (-3.2A) ERM  A2001 (-3.8A) ERM  A2001 (-4.3A) None ERM  A2001 (-4.3A) ERM  A2001 ( 4.8A)	0.54A	28.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	6 / 12	ASP A1113 VAL A1117 SER A1204 SER A1207 ASN A1312 TYR A1316	P0G  A1401 (-2.9A) P0G  A1401 ( 4.4A) P0G  A1401 ( 3.7A) P0G  A1401 (-2.8A) P0G  A1401 (-2.9A) None	1.25A	42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	7 / 12	TRP A1109 ASP A1113 VAL A1114 SER A1203 PHE A1289 ASN A1312 TYR A1316	None P0G  A1401 (-2.9A) P0G  A1401 (-3.7A) P0G  A1401 (-2.9A) P0G  A1401 ( 4.7A) P0G  A1401 (-2.9A) None	1.10A	42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	12 / 12	TRP A1109 ASP A1113 VAL A1114 VAL A1117 PHE A1193 SER A1203 SER A1207 PHE A1289 PHE A1290 ASN A1293 ASN A1312 TYR A1316	None P0G  A1401 (-2.9A) P0G  A1401 (-3.7A) P0G  A1401 ( 4.4A) P0G  A1401 (-3.8A) P0G  A1401 (-2.9A) P0G  A1401 (-2.8A) P0G  A1401 ( 4.7A) P0G  A1401 ( 4.9A) P0G  A1401 (-3.0A) P0G  A1401 (-2.9A) None	0.79A	42.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	4m5y	FAB 5J8 HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 163 VAL H 182 SER H 180 ASN H 197 ASN H 155	None	1.44A	22.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	4ocs	CAP256-VRC26.10 HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 163 VAL H 182 SER H 180 ASN H 197 ASN H 155	None	1.43A	20.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	4py8	ANTIBODY 3.1 HEAVY CHAIN (Homo sapiens)	5 / 12	VAL I 168 VAL I 187 SER I 185 ASN I 202 ASN I 160	None	1.35A	19.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	4rnr	PGT130 HEAVY CHAIN (Homo sapiens)	5 / 12	VAL A 163 VAL A 182 SER A 180 ASN A 197 ASN A 155	None	1.43A	22.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	4zs6	FAB HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 171 VAL H 190 SER H 188 ASN H 205 ASN H 163	None	1.44A	20.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	5anm	IMMUNOGLOBULIN G (Homo sapiens)	5 / 12	VAL B 171 VAL B 190 SER B 188 ASN B 205 ASN B 163	None	1.43A	21.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	5cck	ANTIBODY 3BC315 FAB HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 163 VAL H 182 SER H 180 ASN H 197 ASN H 155	None	1.39A	21.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	5dur	HEAVY CHAIN OF ANTIBODY 100F4 (Homo sapiens)	5 / 12	VAL H 171 VAL H 190 SER H 188 ASN H 205 ASN H 163	None	1.40A	21.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	5ea0	HEAVY CHAIN OF ANTIBODY 7968 FAB FRAGMENT (Homo sapiens)	5 / 12	VAL H 165 VAL H 184 SER H 182 ASN H 199 ASN H 157	None	1.45A	21.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	5fuz	645 FAB, HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 171 VAL H 190 SER H 188 ASN H 205 ASN H 163	None	1.44A	23.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	5i8e	VRC34.01 FAB HEAVY CHAIN (Homo sapiens)	5 / 12	VAL A 163 VAL A 182 SER A 180 ASN A 197 ASN A 155	None	1.37A	20.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	5n4g	HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 165 VAL H 184 SER H 182 ASN H 199 ASN H 157	None	1.45A	18.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	5t3s	FAB 35022 HEAVY CHAIN (Homo sapiens)	5 / 12	VAL D 163 VAL D 182 SER D 180 ASN D 197 ASN D 155	None	1.45A	20.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	5uy3	ANTIBODY PGT144 FAB HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 168 VAL H 187 SER H 185 ASN H 202 ASN H 160	None	1.45A	21.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	5v54	5-HYDROXYTRYPTAMINE RECEPTOR 1B,OB-1 FUSED 5-HT1B RECEPTOR,5-HYDROXYTR YPTAMINE RECEPTOR 1B (Homo sapiens; Spodoptera frugiperda)	6 / 12	TRP A 125 ASP A 129 SER A 212 PHE A 330 PHE A 331 TYR A 359	None 89F  A1201 (-3.3A) 89F  A1201 ( 3.8A) 89F  A1201 (-4.1A) 89F  A1201 (-4.6A) None	0.76A	14.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	5w6g	6649 ANTIBODY HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 175 VAL H 194 SER H 192 ASN H 209 ASN H 167	None	1.41A	13.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wcd	VRC315 04-1D02 FAB HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 174 VAL H 193 SER H 191 ASN H 208 ASN H 166	None	1.43A	22.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	6 / 12	ASP A 115 VAL A 116 SER A 196 PHE A 410 PHE A 411 TYR A 438	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-2.8A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	1.01A	32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	6 / 12	ASP A 115 VAL A 116 SER A 196 PHE A 410 PHE A 411 TYR A 438	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-2.8A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	1.16A	32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	6 / 12	ASP A 115 VAL A 116 SER A 200 PHE A 410 PHE A 411 TYR A 438	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-3.6A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	0.83A	32.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	7 / 12	TRP A 130 ASP A 134 SER A 219 PHE A 327 PHE A 328 ASN A 331 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.2A) E2J  A1201 (-4.6A) E2J  A1201 (-4.4A) None None	1.04A	14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	6 / 12	TRP A 130 ASP A 134 SER A 219 PHE A 327 PHE A 328 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.2A) E2J  A1201 (-4.6A) E2J  A1201 (-4.4A) None	1.23A	14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	6 / 12	TRP A 130 ASP A 134 VAL A 135 PHE A 327 PHE A 328 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.8A) E2J  A1201 (-4.6A) E2J  A1201 (-4.4A) None	0.68A	14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	6cm4	D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA (Escherichia virus T4; Homo sapiens)	5 / 12	ASP A 114 VAL A 115 PHE A 189 PHE A 389 PHE A 390	8NU  A2001 ( 3.0A) 8NU  A2001 ( 3.5A) None 8NU  A2001 ( 4.5A) 8NU  A2001 ( 4.8A)	1.27A	18.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	6cm4	D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA (Escherichia virus T4; Homo sapiens)	5 / 12	ASP A 114 VAL A 115 PHE A 389 PHE A 390 TYR A 416	8NU  A2001 ( 3.0A) 8NU  A2001 ( 3.5A) 8NU  A2001 ( 4.5A) 8NU  A2001 ( 4.8A) 8NU  A2001 ( 4.9A)	0.61A	18.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5  S 401 (-3.3A) EP5  S 401 (-3.3A) EP5  S 401 (-4.0A) EP5  S 401 (-4.7A) EP5  S 401 ( 4.9A)	0.79A	14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_A_5FWA601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 TYR S 359	None EP5  S 401 (-3.3A) EP5  S 401 (-3.3A) EP5  S 401 (-4.0A) EP5  S 401 ( 4.9A)	0.98A	14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	2fl5	IMMUNOGLOBULIN IGG1 HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 171 VAL H 191 SER H 189 ASN H 209 ASN H 162	None	1.42A	22.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	2yk1	FAB FRAGMENT, HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 163 VAL H 182 SER H 180 ASN H 197 ASN H 155	None	1.46A	21.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	3mlx	HUMAN MONOCLONAL ANTI-HIV-1 GP120 V3 ANTIBODY 3074 FAB HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 163 VAL H 182 SER H 180 ASN H 197 ASN H 155	None	1.46A	20.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	6 / 12	ASP A 110 VAL A 111 SER A 192 PHE A 345 PHE A 346 TYR A 373	ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 (-3.3A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	0.85A	29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	6 / 12	ASP A 110 VAL A 111 SER A 192 PHE A 345 PHE A 346 TYR A 373	ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 (-3.3A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	1.03A	29.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Escherichia virus T4; Homo sapiens)	6 / 12	ASP A 110 VAL A 111 SER A 196 PHE A 345 PHE A 346 TYR A 373	ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 ( 4.6A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	0.63A	29.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	9 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 207 PHE A 289 PHE A 290 ASN A 312 TYR A 316	None ERC  A1201 ( 4.6A) ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) ERC  A1201 (-2.7A) ERC  A1201 (-4.5A) ERC  A1201 (-4.8A) ERC  A1201 (-3.0A) None	1.30A	42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	12 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 VAL A 117 SER A 203 SER A 207 PHE A 289 PHE A 290 ASN A 293 ASN A 312 TYR A 316	None ERC  A1201 ( 4.6A) ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) None ERC  A1201 (-2.8A) ERC  A1201 (-2.7A) ERC  A1201 (-4.5A) ERC  A1201 (-4.8A) ERC  A1201 (-3.5A) ERC  A1201 (-3.0A) None	0.43A	42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	6 / 12	VAL A 117 SER A 204 SER A 207 ASN A 293 ASN A 312 TYR A 316	None ERC  A1201 ( 4.1A) ERC  A1201 (-2.7A) ERC  A1201 (-3.5A) ERC  A1201 (-3.0A) None	1.40A	42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Escherichia virus T4; Homo sapiens)	5 / 12	VAL A 117 SER A 207 PHE A 289 ASN A 312 TYR A 316	None ERC  A1201 (-2.7A) ERC  A1201 (-4.5A) ERC  A1201 (-3.0A) None	1.32A	42.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	6 / 12	TRP A 109 ASP A 113 VAL A 114 SER A 207 PHE A 262 TYR A 288	None CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.1A) CAU  A 500 (-4.6A) CAU  A 500 (-4.6A)	1.48A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	6 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 PHE A 261	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.3A) CAU  A 500 (-4.2A)	1.37A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	10 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 VAL A 117 PHE A 261 PHE A 262 ASN A 265 ASN A 284 TYR A 288	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.2A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A) CAU  A 500 (-3.4A) CAU  A 500 (-3.3A) CAU  A 500 (-4.6A)	0.56A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	9 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 VAL A 117 SER A 203 PHE A 261 PHE A 262 TYR A 288	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.2A) CAU  A 500 (-3.3A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A) CAU  A 500 (-4.6A)	0.59A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	5 / 12	TRP A 109 THR A 110 VAL A 114 SER A 203 SER A 207	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.3A) CAU  A 500 (-4.1A)	0.93A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	5 / 12	TRP A 109 THR A 110 VAL A 114 SER A 207 ASN A 265	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.1A) CAU  A 500 (-3.4A)	0.90A	58.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	5 / 12	VAL A 117 PHE A 261 ASN A 265 ASN A 284 TYR A 288	CAU  A 500 (-4.2A) CAU  A 500 (-4.2A) CAU  A 500 (-3.4A) CAU  A 500 (-3.3A) CAU  A 500 (-4.6A)	1.28A	58.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	4ib4	CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	7 / 12	TRP A 131 ASP A 135 VAL A 136 PHE A 340 PHE A 341 ASN A 344 TYR A 370	None ERM  A2001 (-3.2A) ERM  A2001 (-3.8A) ERM  A2001 (-4.3A) None ERM  A2001 (-4.3A) ERM  A2001 ( 4.8A)	0.55A	28.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	7 / 12	ASP A1113 VAL A1117 SER A1204 SER A1207 ASN A1293 ASN A1312 TYR A1316	P0G  A1401 (-2.9A) P0G  A1401 ( 4.4A) P0G  A1401 ( 3.7A) P0G  A1401 (-2.8A) P0G  A1401 (-3.0A) P0G  A1401 (-2.9A) None	1.40A	42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	8 / 12	TRP A1109 THR A1110 ASP A1113 VAL A1114 SER A1203 PHE A1289 ASN A1312 TYR A1316	None P0G  A1401 ( 3.9A) P0G  A1401 (-2.9A) P0G  A1401 (-3.7A) P0G  A1401 (-2.9A) P0G  A1401 ( 4.7A) P0G  A1401 (-2.9A) None	1.09A	42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	12 / 12	TRP A1109 THR A1110 ASP A1113 VAL A1114 VAL A1117 SER A1203 SER A1207 PHE A1289 PHE A1290 ASN A1293 ASN A1312 TYR A1316	None P0G  A1401 ( 3.9A) P0G  A1401 (-2.9A) P0G  A1401 (-3.7A) P0G  A1401 ( 4.4A) P0G  A1401 (-2.9A) P0G  A1401 (-2.8A) P0G  A1401 ( 4.7A) P0G  A1401 ( 4.9A) P0G  A1401 (-3.0A) P0G  A1401 (-2.9A) None	0.65A	42.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Escherichia virus T4; Homo sapiens)	5 / 12	VAL A1117 SER A1207 PHE A1289 PHE A1290 ASN A1293	P0G  A1401 ( 4.4A) P0G  A1401 (-2.8A) P0G  A1401 ( 4.7A) P0G  A1401 ( 4.9A) P0G  A1401 (-3.0A)	1.44A	42.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	4ocs	CAP256-VRC26.10 HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 163 VAL H 182 SER H 180 ASN H 197 ASN H 155	None	1.48A	20.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	4py8	ANTIBODY 3.1 HEAVY CHAIN (Homo sapiens)	5 / 12	VAL I 168 VAL I 187 SER I 185 ASN I 202 ASN I 160	None	1.42A	19.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	4rnr	PGT130 HEAVY CHAIN (Homo sapiens)	5 / 12	VAL A 163 VAL A 182 SER A 180 ASN A 197 ASN A 155	None	1.46A	22.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	4zs6	FAB HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 171 VAL H 190 SER H 188 ASN H 205 ASN H 163	None	1.48A	20.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	5anm	IMMUNOGLOBULIN G (Homo sapiens)	5 / 12	VAL B 171 VAL B 190 SER B 188 ASN B 205 ASN B 163	None	1.48A	21.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	5cck	ANTIBODY 3BC315 FAB HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 163 VAL H 182 SER H 180 ASN H 197 ASN H 155	None	1.42A	21.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	5dur	HEAVY CHAIN OF ANTIBODY 100F4 (Homo sapiens)	5 / 12	VAL H 171 VAL H 190 SER H 188 ASN H 205 ASN H 163	None	1.45A	21.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	5fuz	645 FAB, HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 171 VAL H 190 SER H 188 ASN H 205 ASN H 163	None	1.49A	23.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	5v54	5-HYDROXYTRYPTAMINE RECEPTOR 1B,OB-1 FUSED 5-HT1B RECEPTOR,5-HYDROXYTR YPTAMINE RECEPTOR 1B (Homo sapiens; Spodoptera frugiperda)	6 / 12	TRP A 125 ASP A 129 SER A 212 PHE A 330 PHE A 331 TYR A 359	None 89F  A1201 (-3.3A) 89F  A1201 ( 3.8A) 89F  A1201 (-4.1A) 89F  A1201 (-4.6A) None	0.77A	14.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	5w6g	6649 ANTIBODY HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 175 VAL H 194 SER H 192 ASN H 209 ASN H 167	None	1.45A	13.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wcd	VRC315 04-1D02 FAB HEAVY CHAIN (Homo sapiens)	5 / 12	VAL H 174 VAL H 193 SER H 191 ASN H 208 ASN H 166	None	1.47A	22.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	6 / 12	ASP A 115 VAL A 116 SER A 196 PHE A 410 PHE A 411 TYR A 438	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-2.8A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	0.97A	32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	6 / 12	ASP A 115 VAL A 116 SER A 196 PHE A 410 PHE A 411 TYR A 438	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-2.8A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	1.15A	32.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	6 / 12	ASP A 115 VAL A 116 SER A 200 PHE A 410 PHE A 411 TYR A 438	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-3.6A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	0.79A	32.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bfn	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 (Homo sapiens)	5 / 12	THR A 407 ASP A 404 VAL A 403 SER A 335 SER A 365	None	1.16A	14.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	7 / 12	TRP A 130 ASP A 134 SER A 219 PHE A 327 PHE A 328 ASN A 331 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.2A) E2J  A1201 (-4.6A) E2J  A1201 (-4.4A) None None	1.03A	14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	6 / 12	TRP A 130 ASP A 134 SER A 219 PHE A 327 PHE A 328 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.2A) E2J  A1201 (-4.6A) E2J  A1201 (-4.4A) None	1.25A	14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	6 / 12	TRP A 130 ASP A 134 VAL A 135 PHE A 327 PHE A 328 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.8A) E2J  A1201 (-4.6A) E2J  A1201 (-4.4A) None	0.67A	14.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	6cm4	D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA (Escherichia virus T4; Homo sapiens)	5 / 12	ASP A 114 VAL A 115 PHE A 389 PHE A 390 TYR A 416	8NU  A2001 ( 3.0A) 8NU  A2001 ( 3.5A) 8NU  A2001 ( 4.5A) 8NU  A2001 ( 4.8A) 8NU  A2001 ( 4.9A)	0.61A	18.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	6cm4	D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA (Escherichia virus T4; Homo sapiens)	5 / 12	ASP A 114 VAL A 115 SER A 193 PHE A 389 PHE A 390	8NU  A2001 ( 3.0A) 8NU  A2001 ( 3.5A) 8NU  A2001 ( 4.5A) 8NU  A2001 ( 4.5A) 8NU  A2001 ( 4.8A)	0.99A	18.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5  S 401 (-3.3A) EP5  S 401 (-3.3A) EP5  S 401 (-4.0A) EP5  S 401 (-4.7A) EP5  S 401 ( 4.9A)	0.76A	14.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y03_B_5FWB601_1 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	5 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 TYR S 359	None EP5  S 401 (-3.3A) EP5  S 401 (-3.3A) EP5  S 401 (-4.0A) EP5  S 401 ( 4.9A)	0.98A	14.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4A7T_A_5FWA1000_1 (SUPEROXIDE DISMUTASE [CU-ZN])	1p1v	SUPEROXIDE DISMUTASE [CU-ZN] (Homo sapiens)	4 / 6	GLU A  21 LYS A  23 PRO A  28 TRP A  32	None	1.34A	98.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4A7T_A_5FWA1000_1 (SUPEROXIDE DISMUTASE [CU-ZN])	1p1v	SUPEROXIDE DISMUTASE [CU-ZN] (Homo sapiens)	4 / 6	GLU A  21 PRO A  28 TRP A  32 GLU A 100	None	0.74A	98.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1000_1 (SUPEROXIDE DISMUTASE [CU-ZN])	4po6	INTERFERON ALPHA/BETA RECEPTOR 1 NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	4 / 6	GLU B 500 PRO A 506 LYS B 501 GLU A 517	None	1.33A	11.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4A7T_A_5FWA1000_1 (SUPEROXIDE DISMUTASE [CU-ZN])	4xcr	SUPEROXIDE DISMUTASE [CU-ZN] (Homo sapiens)	4 / 6	GLU A  21 PRO A  28 LYS A  30 GLU A  70	None	0.64A	67.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4A7T_A_5FWA1000_1 (SUPEROXIDE DISMUTASE [CU-ZN])	4xcr	SUPEROXIDE DISMUTASE [CU-ZN] (Homo sapiens)	4 / 6	LYS A  23 PRO A  28 LYS A  30 GLU A  70	None	0.87A	67.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4A7T_A_5FWA1000_1 (SUPEROXIDE DISMUTASE [CU-ZN])	5j0g	OXIDOREDUCTASE,SUPER OXIDE DISMUTASE [CU-ZN] (Homo sapiens)	4 / 6	GLU A  39 PRO A  46 LYS A  48 GLU A  88	None	0.67A	56.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4A7T_A_5FWA1000_1 (SUPEROXIDE DISMUTASE [CU-ZN])	5j0g	OXIDOREDUCTASE,SUPER OXIDE DISMUTASE [CU-ZN] (Homo sapiens)	4 / 6	LYS A  41 PRO A  46 LYS A  48 GLU A  88	None	0.59A	56.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1000_1 (SUPEROXIDE DISMUTASE [CU-ZN])	6dd3	CYTOSOLIC PURINE 5'-NUCLEOTIDASE (Homo sapiens)	4 / 6	LYS A   3 PRO A  63 LYS A  61 GLU A  64	None	1.30A	18.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	1ldk	CULLIN HOMOLOG (Homo sapiens)	3 / 3	ASP B 458 LYS B 459 ASP B 460	None	0.81A	16.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	2dn9	DNAJ HOMOLOG SUBFAMILY A MEMBER 3 (Homo sapiens)	3 / 3	ASP A  42 LYS A  41 ASP A  43	None	0.72A	19.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	2jr7	DPH3 HOMOLOG (Homo sapiens)	3 / 3	ASP A  62 LYS A  61 ASP A  60	None	0.69A	20.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	2k7b	CALCIUM-BINDING PROTEIN 1 (Homo sapiens)	3 / 3	ASP A  39 LYS A  38 ASP A  35	MG  A 601 (-3.5A) None MG  A 601 (-3.3A)	0.76A	22.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	2knx	PROLOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1 (Homo sapiens)	3 / 3	ASP A  30 LYS A  31 ASP A  32	None None CA  A  51 (-3.8A)	0.82A	17.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	2kny	LRP-1, LINKER, APO-E (Homo sapiens)	3 / 3	ASP A  30 LYS A  31 ASP A  32	None None CA  A  81 (-3.1A)	0.73A	24.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	2mux	UBIQUITIN CARBOXYL-TERMINAL HYDROLASE 25 (Homo sapiens)	3 / 3	ASP A  98 LYS A  99 ASP A 101	None	0.80A	21.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	2n80	RHO GDP-DISSOCIATION INHIBITOR 1 (Homo sapiens)	3 / 3	ASP B  42 LYS B  43 ASP B  45	None	0.72A	22.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	3ctz	XAA-PRO AMINOPEPTIDASE 1 (Homo sapiens)	3 / 3	ASP A 579 LYS A 580 ASP A 583	None	0.82A	13.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	3iu1	GLYCYLPEPTIDE N-TETRADECANOYLTRANS FERASE 1 (Homo sapiens)	3 / 3	ASP A 141 LYS A 142 ASP A 143	None	0.83A	17.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	3mew	SAGA-ASSOCIATED FACTOR 29 HOMOLOG (Homo sapiens)	3 / 3	ASP A 196 LYS A 200 ASP A 194	None	0.80A	20.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	4xct	MATRIX METALLOPROTEINASE-9, MATRIX METALLOPROTEINASE-9 (Homo sapiens)	3 / 3	ASP A 259 LYS A 258 ASP A 260	None	0.84A	20.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	5hn1	INTERLEUKIN-37 (Homo sapiens)	3 / 3	ASP A 125 LYS A 124 ASP A 123	None None SO4  A 302 (-4.5A)	0.85A	16.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	5ku1	MITOCHONDRIAL RHO GTPASE 1 (Homo sapiens)	3 / 3	ASP A 296 LYS A 405 ASP A 404	None	0.75A	17.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	5mgt	KILLER CELL LECTIN-LIKE RECEPTOR SUBFAMILY B MEMBER 1 (Homo sapiens)	3 / 3	ASP C 136 LYS C 135 ASP C 134	None	0.86A	undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	5n48	NEUTROPHIL GELATINASE-ASSOCIATE D LIPOCALIN (Homo sapiens)	3 / 3	ASP A  47 LYS A  46 ASP A  45	None	0.79A	20.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	5th6	MATRIX METALLOPROTEINASE-9, MATRIX METALLOPROTEINASE-9 (Homo sapiens)	3 / 3	ASP A 434 LYS A 433 ASP A 435	None	0.82A	21.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	6bq8	CGMP-DEPENDENT PROTEIN KINASE 2 (Homo sapiens)	3 / 3	ASP A 308 LYS A 309 ASP A 311	None	0.85A	16.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1002_1 (SUPEROXIDE DISMUTASE [CU-ZN])	2pid	TYROSYL-TRNA SYNTHETASE (Homo sapiens)	3 / 3	ASN A 173 TRP A 176 ASP A  81	YSA  A 384 ( 4.8A) None YSA  A 384 (-3.9A)	0.78A	17.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1002_1 (SUPEROXIDE DISMUTASE [CU-ZN])	2qp4	BILE SALT SULFOTRANSFERASE (Homo sapiens)	3 / 3	ASN A 122 TRP A 284 ASP A 253	None	1.15A	20.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1002_1 (SUPEROXIDE DISMUTASE [CU-ZN])	3iiw	POLYCOMB PROTEIN EED (Homo sapiens)	3 / 3	ASN A 102 TRP A 152 ASP A 109	None	1.23A	17.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1002_1 (SUPEROXIDE DISMUTASE [CU-ZN])	3zyj	LEUCINE-RICH REPEAT-CONTAINING PROTEIN 4C NETRIN-G1 (Homo sapiens)	3 / 3	ASN B  84 TRP A 154 ASP A 225	None	1.09A	16.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1002_1 (SUPEROXIDE DISMUTASE [CU-ZN])	4ued	EUKARYOTIC TRANSLATION INITIATION FACTOR 4E (Homo sapiens)	3 / 3	ASN A  41 TRP A  43 ASP A 147	None	1.27A	20.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1002_1 (SUPEROXIDE DISMUTASE [CU-ZN])	4uis	GAMMA-SECRETASE (Homo sapiens)	3 / 3	ASN A 290 TRP A 289 ASP A 548	None	0.91A	13.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1002_1 (SUPEROXIDE DISMUTASE [CU-ZN])	5ei3	EUKARYOTIC TRANSLATION INITIATION FACTOR 4E (Homo sapiens)	3 / 3	ASN A  41 TRP A  43 ASP A 147	None	1.27A	22.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1002_1 (SUPEROXIDE DISMUTASE [CU-ZN])	5f7h	T-CELL IMMUNOGLOBULIN AND MUCIN DOMAIN-CONTAINING PROTEIN 4 (Homo sapiens)	3 / 3	ASN B  29 TRP B  24 ASP B 101	None None CA  B 201 ( 3.1A)	1.28A	22.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1002_1 (SUPEROXIDE DISMUTASE [CU-ZN])	5j6s	ENDOPLASMIC RETICULUM AMINOPEPTIDASE 2 (Homo sapiens)	3 / 3	ASN A 948 TRP A 944 ASP A 678	None	0.95A	11.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1002_1 (SUPEROXIDE DISMUTASE [CU-ZN])	5xtb	NADH DEHYDROGENASE [UBIQUINONE] IRON-SULFUR PROTEIN 4, MITOCHONDRIAL NADH-UBIQUINONE OXIDOREDUCTASE 75 KDA SUBUNIT, MITOCHONDRIAL (Homo sapiens)	3 / 3	ASN L 167 TRP L 166 ASP M 426	None	0.88A	21.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_A_5FWA1002_1 (SUPEROXIDE DISMUTASE [CU-ZN])	6ba5	INACTIVE TYROSINE-PROTEIN KINASE TRANSMEMBRANE RECEPTOR ROR1 VARIABLE DOMAIN HEAVY CHAIN, ANTIBODY R11 VARIABLE DOMAIN OF LIGHT CHAIN, ANTIBODY R11 (Homo sapiens)	3 / 3	ASN A  95 TRP B  57 ASP M 378	None	1.27A	22.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_F_5FWF1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	1dbh	PROTEIN (HUMAN SOS 1) (Homo sapiens)	4 / 6	GLU A 361 LYS A 370 LYS A 363 GLU A 365	None	1.43A	16.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4A7T_F_5FWF1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	1p1v	SUPEROXIDE DISMUTASE [CU-ZN] (Homo sapiens)	4 / 6	GLU A  21 PRO A  28 TRP A  32 GLU A 100	None	0.73A	98.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_F_5FWF1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	1xdv	SON OF SEVENLESS PROTEIN HOMOLOG 1 (Homo sapiens)	4 / 6	GLU A 361 LYS A 370 LYS A 363 GLU A 365	None	1.43A	9.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_F_5FWF1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	2de0	ALPHA-(1,6)-FUCOSYLT RANSFERASE (Homo sapiens)	4 / 6	GLU X 183 PRO X 484 LYS X 185 GLU X 181	None	1.24A	15.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_F_5FWF1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	3n93	MALTOSE BINDING PROTEIN-CRFR2 ALPHA (Homo sapiens)	4 / 6	GLU A-367 LYS A-369 PRO A -99 GLU A-366	None	1.36A	16.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_F_5FWF1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	3zyx	AMINE OXIDASE [FLAVIN-CONTAINING] B (Homo sapiens)	4 / 6	GLU A 366 LYS A 362 PRO A 380 GLU A 379	None	1.36A	16.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4A7T_F_5FWF1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	4po6	INTERFERON ALPHA/BETA RECEPTOR 1 NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	4 / 6	GLU B 500 PRO A 506 LYS B 501 GLU A 517	None	1.34A	11.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4A7T_F_5FWF1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	4xcr	SUPEROXIDE DISMUTASE [CU-ZN] (Homo sapiens)	4 / 6	GLU A  21 PRO A  28 LYS A  30 GLU A  70	None	0.73A	67.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4A7T_F_5FWF1001_1 (SUPEROXIDE DISMUTASE [CU-ZN])	5j0g	OXIDOREDUCTASE,SUPER OXIDE DISMUTASE [CU-ZN] (Homo sapiens)	4 / 6	GLU A  39 PRO A  46 LYS A  48 GLU A  88	None	0.75A	56.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	2xyd	ANGIOTENSIN-CONVERTI NG ENZYME (Homo sapiens)	5 / 12	TRP A  40 THR A  44 SER A 123 SER A 119 PHE A 490	None None None None 3ES  A1611 (-4.7A)	1.39A	9.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Homo sapiens; Escherichia virus T4)	5 / 12	ASP A 110 VAL A 111 SER A 192 PHE A 345 PHE A 346	ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 (-3.3A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A)	1.24A	9.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Homo sapiens; Escherichia virus T4)	6 / 12	ASP A 110 VAL A 111 SER A 192 PHE A 345 PHE A 346 TYR A 373	ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 (-3.3A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	0.79A	9.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Homo sapiens; Escherichia virus T4)	6 / 12	ASP A 110 VAL A 111 SER A 196 PHE A 345 PHE A 346 TYR A 373	ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 ( 4.6A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	0.53A	9.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	5 / 12	SER A 204 SER A 207 PHE A 289 ASN A 293 ASN A 312	ERC  A1201 ( 4.1A) ERC  A1201 (-2.7A) ERC  A1201 (-4.5A) ERC  A1201 (-3.5A) ERC  A1201 (-3.0A)	1.35A	13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	6 / 12	TRP A 109 THR A 110 ASP A 113 SER A 203 SER A 207 ASN A 312	None ERC  A1201 ( 4.6A) ERC  A1201 (-3.7A) ERC  A1201 (-2.8A) ERC  A1201 (-2.7A) ERC  A1201 (-3.0A)	1.03A	13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	10 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 SER A 204 PHE A 289 PHE A 290 ASN A 312 TYR A 316	None ERC  A1201 ( 4.6A) ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) ERC  A1201 (-2.8A) ERC  A1201 ( 4.1A) ERC  A1201 (-4.5A) ERC  A1201 (-4.8A) ERC  A1201 (-3.0A) None	0.58A	13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	11 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 SER A 204 SER A 207 PHE A 289 PHE A 290 ASN A 293 ASN A 312	None ERC  A1201 ( 4.6A) ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) ERC  A1201 (-2.8A) ERC  A1201 ( 4.1A) ERC  A1201 (-2.7A) ERC  A1201 (-4.5A) ERC  A1201 (-4.8A) ERC  A1201 (-3.5A) ERC  A1201 (-3.0A)	0.70A	13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	9 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 207 PHE A 289 PHE A 290 ASN A 312 TYR A 316	None ERC  A1201 ( 4.6A) ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) ERC  A1201 (-2.7A) ERC  A1201 (-4.5A) ERC  A1201 (-4.8A) ERC  A1201 (-3.0A) None	1.20A	13.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	5 / 12	THR A 110 VAL A 114 SER A 204 PHE A 262 ASN A 265	CAU  A 500 ( 4.0A) CAU  A 500 (-3.5A) None CAU  A 500 (-4.6A) CAU  A 500 (-3.4A)	0.92A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	5 / 12	THR A 110 VAL A 114 SER A 204 SER A 207 ASN A 265	CAU  A 500 ( 4.0A) CAU  A 500 (-3.5A) None CAU  A 500 (-4.1A) CAU  A 500 (-3.4A)	0.97A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	9 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 PHE A 261 PHE A 262 ASN A 265 ASN A 284 TYR A 288	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A) CAU  A 500 (-3.4A) CAU  A 500 (-3.3A) CAU  A 500 (-4.6A)	0.66A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	8 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 PHE A 261 PHE A 262 TYR A 288	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.3A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A) CAU  A 500 (-4.6A)	0.68A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	7 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 207 PHE A 262 TYR A 288	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.1A) CAU  A 500 (-4.6A) CAU  A 500 (-4.6A)	1.28A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	5 / 12	TRP A 109 THR A 110 VAL A 114 SER A 203 SER A 207	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.3A) CAU  A 500 (-4.1A)	0.94A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	5 / 12	TRP A 109 THR A 110 VAL A 114 SER A 207 ASN A 265	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.1A) CAU  A 500 (-3.4A)	0.98A	59.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	4ib4	CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	5 / 12	TRP A 131 ASP A 135 SER A 222 ASN A 344 TYR A 370	None ERM  A2001 (-3.2A) ERM  A2001 ( 4.6A) ERM  A2001 (-4.3A) ERM  A2001 ( 4.8A)	1.26A	10.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	4ib4	CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	8 / 12	TRP A 131 ASP A 135 VAL A 136 SER A 222 PHE A 340 PHE A 341 ASN A 344 TYR A 370	None ERM  A2001 (-3.2A) ERM  A2001 (-3.8A) ERM  A2001 ( 4.6A) ERM  A2001 (-4.3A) None ERM  A2001 (-4.3A) ERM  A2001 ( 4.8A)	0.53A	10.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Homo sapiens; Escherichia virus T4)	6 / 12	ASP A1113 SER A1204 SER A1207 ASN A1293 ASN A1312 TYR A1316	P0G  A1401 (-2.9A) P0G  A1401 ( 3.7A) P0G  A1401 (-2.8A) P0G  A1401 (-3.0A) P0G  A1401 (-2.9A) None	1.19A	22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Homo sapiens; Escherichia virus T4)	6 / 12	TRP A1109 ASP A1113 SER A1203 SER A1207 ASN A1312 TYR A1316	None P0G  A1401 (-2.9A) P0G  A1401 (-2.9A) P0G  A1401 (-2.8A) P0G  A1401 (-2.9A) None	1.17A	22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Homo sapiens; Escherichia virus T4)	12 / 12	TRP A1109 THR A1110 ASP A1113 VAL A1114 SER A1203 SER A1204 SER A1207 PHE A1289 PHE A1290 ASN A1293 ASN A1312 TYR A1316	None P0G  A1401 ( 3.9A) P0G  A1401 (-2.9A) P0G  A1401 (-3.7A) P0G  A1401 (-2.9A) P0G  A1401 ( 3.7A) P0G  A1401 (-2.8A) P0G  A1401 ( 4.7A) P0G  A1401 ( 4.9A) P0G  A1401 (-3.0A) P0G  A1401 (-2.9A) None	0.40A	22.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	5v54	5-HYDROXYTRYPTAMINE RECEPTOR 1B,OB-1 FUSED 5-HT1B RECEPTOR,5-HYDROXYTR YPTAMINE RECEPTOR 1B (Spodoptera frugiperda; Homo sapiens)	6 / 12	TRP A 125 ASP A 129 SER A 212 PHE A 330 PHE A 331 TYR A 359	None 89F  A1201 (-3.3A) 89F  A1201 ( 3.8A) 89F  A1201 (-4.1A) 89F  A1201 (-4.6A) None	0.71A	32.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	7 / 12	ASP A 115 VAL A 116 SER A 196 SER A 197 PHE A 410 PHE A 411 TYR A 438	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-2.8A) AQD  A1201 ( 4.0A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	0.89A	15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	6 / 12	ASP A 115 VAL A 116 SER A 197 SER A 196 PHE A 410 PHE A 411	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 ( 4.0A) AQD  A1201 (-2.8A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A)	1.33A	15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	7 / 12	ASP A 115 VAL A 116 SER A 197 SER A 200 PHE A 410 PHE A 411 TYR A 438	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 ( 4.0A) AQD  A1201 (-3.6A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	0.67A	15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	6b5c	KATANIN P60 ATPASE-CONTAINING SUBUNIT A-LIKE 1 (Homo sapiens)	5 / 12	THR A 255 SER A 273 SER A 275 SER A 274 ASN A 359	None	1.40A	19.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	6bfn	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 (Homo sapiens)	5 / 12	THR A 407 ASP A 404 VAL A 403 SER A 335 SER A 365	None	1.14A	20.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	5 / 12	TRP A 130 ASP A 134 SER A 219 PHE A 327 PHE A 328	None E2J  A1201 (-3.0A) E2J  A1201 (-3.2A) E2J  A1201 (-4.6A) E2J  A1201 (-4.4A)	1.32A	17.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	7 / 12	TRP A 130 ASP A 134 SER A 219 PHE A 327 PHE A 328 ASN A 331 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.2A) E2J  A1201 (-4.6A) E2J  A1201 (-4.4A) None None	0.87A	17.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	7 / 12	TRP A 130 ASP A 134 VAL A 135 SER A 219 PHE A 327 PHE A 328 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.8A) E2J  A1201 (-3.2A) E2J  A1201 (-4.6A) E2J  A1201 (-4.4A) None	0.71A	17.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	6cm4	D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA (Homo sapiens; Escherichia virus T4)	6 / 12	ASP A 114 VAL A 115 SER A 194 PHE A 389 PHE A 390 TYR A 416	8NU  A2001 ( 3.0A) 8NU  A2001 ( 3.5A) None 8NU  A2001 ( 4.5A) 8NU  A2001 ( 4.8A) 8NU  A2001 ( 4.9A)	0.53A	42.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	6cm4	D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA (Homo sapiens; Escherichia virus T4)	5 / 12	ASP A 114 VAL A 115 SER A 194 SER A 197 TYR A 416	8NU  A2001 ( 3.0A) 8NU  A2001 ( 3.5A) None 8NU  A2001 ( 3.6A) 8NU  A2001 ( 4.9A)	0.70A	42.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	6cm4	D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA (Homo sapiens; Escherichia virus T4)	5 / 12	VAL A 115 SER A 193 SER A 194 PHE A 389 PHE A 390	8NU  A2001 ( 3.5A) 8NU  A2001 ( 4.5A) None 8NU  A2001 ( 4.5A) 8NU  A2001 ( 4.8A)	0.84A	42.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_A_5FWA401_0 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5  S 401 (-3.3A) EP5  S 401 (-3.3A) EP5  S 401 (-4.0A) EP5  S 401 (-4.7A) EP5  S 401 ( 4.9A)	0.75A	29.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	2xyd	ANGIOTENSIN-CONVERTI NG ENZYME (Homo sapiens)	5 / 12	TRP A  40 THR A  44 SER A 123 SER A 119 PHE A 490	None None None None 3ES  A1611 (-4.7A)	1.38A	9.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Homo sapiens; Escherichia virus T4)	5 / 12	ASP A 110 VAL A 111 SER A 192 PHE A 345 PHE A 346	ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 (-3.3A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A)	1.25A	9.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Homo sapiens; Escherichia virus T4)	6 / 12	ASP A 110 VAL A 111 SER A 192 PHE A 345 PHE A 346 TYR A 373	ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 (-3.3A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	0.78A	9.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	3pbl	D(3) DOPAMINE RECEPTOR, LYSOZYME CHIMERA (Homo sapiens; Escherichia virus T4)	6 / 12	ASP A 110 VAL A 111 SER A 196 PHE A 345 PHE A 346 TYR A 373	ETQ  A1200 (-3.5A) ETQ  A1200 (-3.4A) ETQ  A1200 ( 4.6A) ETQ  A1200 (-4.4A) ETQ  A1200 ( 4.5A) ETQ  A1200 (-4.4A)	0.53A	9.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	6 / 12	TRP A 109 THR A 110 ASP A 113 SER A 203 SER A 207 ASN A 312	None ERC  A1201 ( 4.6A) ERC  A1201 (-3.7A) ERC  A1201 (-2.8A) ERC  A1201 (-2.7A) ERC  A1201 (-3.0A)	1.02A	13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	10 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 SER A 204 PHE A 289 PHE A 290 ASN A 312 TYR A 316	None ERC  A1201 ( 4.6A) ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) ERC  A1201 (-2.8A) ERC  A1201 ( 4.1A) ERC  A1201 (-4.5A) ERC  A1201 (-4.8A) ERC  A1201 (-3.0A) None	0.58A	13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	11 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 SER A 204 SER A 207 PHE A 289 PHE A 290 ASN A 293 ASN A 312	None ERC  A1201 ( 4.6A) ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) ERC  A1201 (-2.8A) ERC  A1201 ( 4.1A) ERC  A1201 (-2.7A) ERC  A1201 (-4.5A) ERC  A1201 (-4.8A) ERC  A1201 (-3.5A) ERC  A1201 (-3.0A)	0.70A	13.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	3pds	FUSION PROTEIN BETA-2 ADRENERGIC RECEPTOR/LYSOZYME (Homo sapiens; Escherichia virus T4)	9 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 207 PHE A 289 PHE A 290 ASN A 312 TYR A 316	None ERC  A1201 ( 4.6A) ERC  A1201 (-3.7A) ERC  A1201 (-3.8A) ERC  A1201 (-2.7A) ERC  A1201 (-4.5A) ERC  A1201 (-4.8A) ERC  A1201 (-3.0A) None	1.19A	13.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	5 / 12	THR A 110 VAL A 114 SER A 204 PHE A 262 ASN A 265	CAU  A 500 ( 4.0A) CAU  A 500 (-3.5A) None CAU  A 500 (-4.6A) CAU  A 500 (-3.4A)	0.91A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	5 / 12	THR A 110 VAL A 114 SER A 204 SER A 207 ASN A 265	CAU  A 500 ( 4.0A) CAU  A 500 (-3.5A) None CAU  A 500 (-4.1A) CAU  A 500 (-3.4A)	0.97A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	9 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 PHE A 261 PHE A 262 ASN A 265 ASN A 284 TYR A 288	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A) CAU  A 500 (-3.4A) CAU  A 500 (-3.3A) CAU  A 500 (-4.6A)	0.65A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	8 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 203 PHE A 261 PHE A 262 TYR A 288	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.3A) CAU  A 500 (-4.2A) CAU  A 500 (-4.6A) CAU  A 500 (-4.6A)	0.68A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	7 / 12	TRP A 109 THR A 110 ASP A 113 VAL A 114 SER A 207 PHE A 262 TYR A 288	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.1A) CAU  A 500 (-4.6A) CAU  A 500 (-4.6A)	1.27A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	5 / 12	TRP A 109 THR A 110 VAL A 114 SER A 203 SER A 207	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.5A) CAU  A 500 (-3.3A) CAU  A 500 (-4.1A)	0.96A	59.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	4gbr	BETA-2 ADRENERGIC RECEPTOR (Homo sapiens)	5 / 12	TRP A 109 THR A 110 VAL A 114 SER A 207 ASN A 265	None CAU  A 500 ( 4.0A) CAU  A 500 (-3.5A) CAU  A 500 (-4.1A) CAU  A 500 (-3.4A)	0.98A	59.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	4ib4	CHIMERA PROTEIN OF HUMAN 5-HYDROXYTRYPTAMINE RECEPTOR 2B AND E. COLI SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	8 / 12	TRP A 131 ASP A 135 VAL A 136 SER A 222 PHE A 340 PHE A 341 ASN A 344 TYR A 370	None ERM  A2001 (-3.2A) ERM  A2001 (-3.8A) ERM  A2001 ( 4.6A) ERM  A2001 (-4.3A) None ERM  A2001 (-4.3A) ERM  A2001 ( 4.8A)	0.53A	10.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Homo sapiens; Escherichia virus T4)	6 / 12	ASP A1113 SER A1204 SER A1207 ASN A1293 ASN A1312 TYR A1316	P0G  A1401 (-2.9A) P0G  A1401 ( 3.7A) P0G  A1401 (-2.8A) P0G  A1401 (-3.0A) P0G  A1401 (-2.9A) None	1.20A	22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Homo sapiens; Escherichia virus T4)	6 / 12	TRP A1109 ASP A1113 SER A1203 SER A1207 ASN A1312 TYR A1316	None P0G  A1401 (-2.9A) P0G  A1401 (-2.9A) P0G  A1401 (-2.8A) P0G  A1401 (-2.9A) None	1.16A	22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	4lde	LYSOZYME, BETA-2 ADRENERGIC RECEPTOR (Homo sapiens; Escherichia virus T4)	12 / 12	TRP A1109 THR A1110 ASP A1113 VAL A1114 SER A1203 SER A1204 SER A1207 PHE A1289 PHE A1290 ASN A1293 ASN A1312 TYR A1316	None P0G  A1401 ( 3.9A) P0G  A1401 (-2.9A) P0G  A1401 (-3.7A) P0G  A1401 (-2.9A) P0G  A1401 ( 3.7A) P0G  A1401 (-2.8A) P0G  A1401 ( 4.7A) P0G  A1401 ( 4.9A) P0G  A1401 (-3.0A) P0G  A1401 (-2.9A) None	0.39A	22.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	5v54	5-HYDROXYTRYPTAMINE RECEPTOR 1B,OB-1 FUSED 5-HT1B RECEPTOR,5-HYDROXYTR YPTAMINE RECEPTOR 1B (Spodoptera frugiperda; Homo sapiens)	6 / 12	TRP A 125 ASP A 129 SER A 212 PHE A 330 PHE A 331 TYR A 359	None 89F  A1201 (-3.3A) 89F  A1201 ( 3.8A) 89F  A1201 (-4.1A) 89F  A1201 (-4.6A) None	0.70A	32.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	7 / 12	ASP A 115 VAL A 116 SER A 196 SER A 197 PHE A 410 PHE A 411 TYR A 438	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 (-2.8A) AQD  A1201 ( 4.0A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	0.88A	15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	6 / 12	ASP A 115 VAL A 116 SER A 197 SER A 196 PHE A 410 PHE A 411	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 ( 4.0A) AQD  A1201 (-2.8A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A)	1.33A	15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	5wiv	D(4) DOPAMINE RECEPTOR, SOLUBLE CYTOCHROME B562 CHIMERA (Escherichia coli; Homo sapiens)	7 / 12	ASP A 115 VAL A 116 SER A 197 SER A 200 PHE A 410 PHE A 411 TYR A 438	AQD  A1201 (-3.3A) AQD  A1201 ( 3.9A) AQD  A1201 ( 4.0A) AQD  A1201 (-3.6A) AQD  A1201 (-4.7A) AQD  A1201 (-4.6A) None	0.67A	15.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	6b5c	KATANIN P60 ATPASE-CONTAINING SUBUNIT A-LIKE 1 (Homo sapiens)	5 / 12	THR A 255 SER A 273 SER A 275 SER A 274 ASN A 359	None	1.40A	19.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	6bfn	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 (Homo sapiens)	5 / 12	THR A 407 ASP A 404 VAL A 403 SER A 335 SER A 365	None	1.14A	20.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	5 / 12	TRP A 130 ASP A 134 SER A 219 PHE A 327 PHE A 328	None E2J  A1201 (-3.0A) E2J  A1201 (-3.2A) E2J  A1201 (-4.6A) E2J  A1201 (-4.4A)	1.34A	17.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	7 / 12	TRP A 130 ASP A 134 SER A 219 PHE A 327 PHE A 328 ASN A 331 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.2A) E2J  A1201 (-4.6A) E2J  A1201 (-4.4A) None None	0.88A	17.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	6bqh	5-HYDROXYTRYPTAMINE RECEPTOR 2C,SOLUBLE CYTOCHROME B562 (Escherichia coli; Homo sapiens)	7 / 12	TRP A 130 ASP A 134 VAL A 135 SER A 219 PHE A 327 PHE A 328 TYR A 358	None E2J  A1201 (-3.0A) E2J  A1201 (-3.8A) E2J  A1201 (-3.2A) E2J  A1201 (-4.6A) E2J  A1201 (-4.4A) None	0.70A	17.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	6cm4	D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA (Homo sapiens; Escherichia virus T4)	6 / 12	ASP A 114 VAL A 115 SER A 194 PHE A 389 PHE A 390 TYR A 416	8NU  A2001 ( 3.0A) 8NU  A2001 ( 3.5A) None 8NU  A2001 ( 4.5A) 8NU  A2001 ( 4.8A) 8NU  A2001 ( 4.9A)	0.53A	42.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	6cm4	D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA (Homo sapiens; Escherichia virus T4)	5 / 12	ASP A 114 VAL A 115 SER A 194 SER A 197 TYR A 416	8NU  A2001 ( 3.0A) 8NU  A2001 ( 3.5A) None 8NU  A2001 ( 3.6A) 8NU  A2001 ( 4.9A)	0.71A	42.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	6cm4	D(2) DOPAMINE RECEPTOR, ENDOLYSIN CHIMERA (Homo sapiens; Escherichia virus T4)	5 / 12	VAL A 115 SER A 193 SER A 194 PHE A 389 PHE A 390	8NU  A2001 ( 3.5A) 8NU  A2001 ( 4.5A) None 8NU  A2001 ( 4.5A) 8NU  A2001 ( 4.8A)	0.83A	42.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6H7J_B_5FWB402_0 (BETA-1 ADRENERGIC RECEPTOR)	6g79	5-HYDROXYTRYPTAMINE RECEPTOR 1B (Homo sapiens)	6 / 12	TRP S 125 ASP S 129 SER S 212 PHE S 330 PHE S 331 TYR S 359	None EP5  S 401 (-3.3A) EP5  S 401 (-3.3A) EP5  S 401 (-4.0A) EP5  S 401 (-4.7A) EP5  S 401 ( 4.9A)	0.75A	29.79